$STE
STERIS plc Stock $ste

$ste Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000175789822000019 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$1.201B	$1.156B	$1.211B
YoY Change	0.3%	19.42%	38.6%
Cost Of Revenue	$668.2M	$638.7M	$639.1M
YoY Change	-6.76%	17.81%	29.44%
Gross Profit	$532.3M	$517.8M	$571.6M
YoY Change	10.82%	21.47%	50.5%
Gross Profit Margin	44.34%	44.77%	47.21%
Selling, General & Admin	$323.2M	$334.6M	$453.6M
YoY Change	-6.27%	-15.02%	105.17%
% of Gross Profit	60.71%	64.62%	79.36%
Research & Development	$24.93M	$24.75M	$26.10M
YoY Change	32.37%	36.05%	49.13%
% of Gross Profit	4.68%	4.78%	4.57%
Depreciation & Amortization	$133.9M	$138.9M	$233.8M
YoY Change	13.42%	66.06%	296.32%
% of Gross Profit	25.15%	26.82%	40.91%
Operating Expenses	$838.8M	$359.4M	$479.7M
YoY Change	130.53%	-12.76%	101.06%
Operating Profit	-$306.4M	$158.4M	$91.89M
YoY Change	-363.01%	1005.8%	-34.93%
Interest Expense	$26.12M	$22.67M	-$20.39M
YoY Change	13.4%	3.95%	137.14%
% of Operating Profit		14.31%	-22.19%
Other Income/Expense, Net	-$26.65M	-$23.44M	$0.00
YoY Change	-0.93%	-45.86%
Pretax Income	-$333.1M	$135.0M	$71.46M
YoY Change	-471.69%	-565.72%	-48.03%
Income Tax	-$17.83M	$24.20M	$19.41M
% Of Pretax Income		17.93%	27.16%
Net Earnings	-$315.3M	$111.3M	$52.26M
YoY Change	-551.63%	-610.21%	-40.23%
Net Earnings / Revenue	-26.26%	9.62%	4.32%
Basic Earnings Per Share	-$3.15	$1.11	$0.52
Diluted Earnings Per Share	-$3.15	$1.10	$0.52
COMMON SHARES
Basic Shares Outstanding	100.0M shares	100.1M shares	100.1M shares
Diluted Shares Outstanding	99.97M shares	100.7M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$258.3M	$316.3M	$348.3M
YoY Change	-32.66%	-40.85%	57.97%
Cash & Equivalents	$258.3M	$316.3M	$348.3M
Short-Term Investments
Other Short-Term Assets	$205.0M	$147.4M	$156.6M
YoY Change	5.34%	7.93%	134.49%
Inventory	$644.9M	$620.4M	$575.0M
Prepaid Expenses
Receivables	$780.1M	$763.8M	$799.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.888B	$1.848B	$1.879B
YoY Change	-0.86%	-7.96%	55.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.572B	$1.573B	$1.553B
YoY Change	4.05%	4.93%	25.67%
Goodwill	$3.705B	$4.321B	$4.404B
YoY Change	-27.81%	-18.26%	45.55%
Intangibles	$3.077B	$3.193B	$3.329B
YoY Change	4.17%	4.75%	270.49%
Long-Term Investments
YoY Change
Other Assets	$72.23M	$70.16M	$70.66M
YoY Change	44.12%	36.37%	34.03%
Total Long-Term Assets	$8.601B	$9.340B	$9.545B
YoY Change	-12.66%	-7.46%	77.98%
TOTAL ASSETS
Total Short-Term Assets	$1.888B	$1.848B	$1.879B
Total Long-Term Assets	$8.601B	$9.340B	$9.545B
Total Assets	$10.49B	$11.19B	$11.42B
YoY Change	-10.75%	-7.54%	73.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$233.3M	$229.0M	$225.7M
YoY Change	6.41%	-1.38%	43.83%
Accrued Expenses	$304.0M	$317.6M	$306.5M
YoY Change	-1.59%	5.61%	38.99%
Deferred Revenue
YoY Change
Short-Term Debt	$151.0M	$151.0M	$142.9M
YoY Change	590.29%	2096.36%
Long-Term Debt Due	$151.0M	$151.0M	$142.9M
YoY Change	590.29%	2096.36%
Total Short-Term Liabilities	$872.8M	$908.3M	$922.2M
YoY Change	11.09%	-20.67%	59.58%
LONG-TERM LIABILITIES
Long-Term Debt	$2.874B	$2.846B	$2.945B
YoY Change	-16.0%	-12.6%	78.46%
Other Long-Term Liabilities	$75.90M	$73.08M	$75.58M
YoY Change	-9.2%	-15.07%	-14.12%
Total Long-Term Liabilities	$2.950B	$2.920B	$3.021B
YoY Change	-15.84%	-12.66%	73.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$872.8M	$908.3M	$922.2M
Total Long-Term Liabilities	$2.950B	$2.920B	$3.021B
Total Liabilities	$4.676B	$4.769B	$4.879B
YoY Change	-10.2%	-13.54%	81.85%
SHAREHOLDERS EQUITY
Retained Earnings	$1.695B	$2.057B	$1.999B
YoY Change	-10.46%	9.74%	3.09%
Common Stock	$4.705B	$4.739B	$4.743B
YoY Change	-0.91%	0.04%	136.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.802B	$6.408B	$6.532B
YoY Change
Total Liabilities & Shareholders Equity	$10.49B	$11.19B	$11.42B
YoY Change	-10.75%	-7.54%	73.76%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$315.3M	$111.3M	$52.26M
YoY Change	-551.63%	-610.21%	-40.23%
Depreciation, Depletion And Amortization	$133.9M	$138.9M	$233.8M
YoY Change	13.42%	66.06%	296.32%
Cash From Operating Activities	$103.8M	$231.7M	$171.7M
YoY Change	-39.4%	137.87%	-8.56%
INVESTING ACTIVITIES
Capital Expenditures	-$82.77M	$115.9M	-$73.07M
YoY Change	7.53%	105.57%	-2.31%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	-$15.16M	$6.516M	$166.6M
YoY Change	-9015.88%	-101.19%	-483.1%
Cash From Investing Activities	-$97.93M	-$109.4M	$93.58M
YoY Change	27.5%	-81.87%	-179.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$24.68M
YoY Change		131.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-44.95M	-$141.4M	-274.6M
YoY Change	-81.2%	-117.27%	183.39%
NET CHANGE
Cash From Operating Activities	103.8M	$231.7M	171.7M
Cash From Investing Activities	-97.93M	-$109.4M	93.58M
Cash From Financing Activities	-44.95M	-$141.4M	-274.6M
Net Change In Cash	-39.05M	-$31.99M	-9.301M
YoY Change	-72.99%	-110.18%	-66.05%
FREE CASH FLOW
Cash From Operating Activities	$103.8M	$231.7M	$171.7M
Capital Expenditures	-$82.77M	$115.9M	-$73.07M
Free Cash Flow	$186.6M	$115.8M	$244.8M
YoY Change	-24.86%	182.26%	-6.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	STERIS plc
CY2022Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001757898
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100014639	shares
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	dei	Entity File Number EntityFileNumber	001-38848
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1455064
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	1 232 2000
CY2022Q2	dei	City Area Code CityAreaCode	353
CY2022Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23121000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24371000	usd
CY2022Q2	ste	Aggregate Amountof Shares Authorized AggregateAmountofSharesAuthorized	500000000	usd
CY2022Q1	ste	Aggregate Amountof Shares Authorized AggregateAmountofSharesAuthorized	500000000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100090000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100067000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	-6000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	174000	usd
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.40
CY2022Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.43
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	dei	Entity File Number EntityFileNumber	001-38848
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	STERIS plc
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1455064
CY2022Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	70 Sir John Rogerson's Quay,
CY2022Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2,
CY2022Q2	dei	Entity Address Country EntityAddressCountry	IE
CY2022Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 R296
CY2022Q2	dei	City Area Code CityAreaCode	353
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	1 232 2000
CY2022Q2	dei	Security12b Title Security12bTitle	Ordinary Shares, $0.001 par value
CY2022Q2	dei	Trading Symbol TradingSymbol	STE
CY2022Q2	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100014639	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	316327000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	348320000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23121000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24371000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	763788000	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	799041000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	620404000	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	574999000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	147428000	usd
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	156637000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1847947000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	1878997000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1573337000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1552576000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	182357000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	188480000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4321176000	usd
CY2022Q1	us-gaap	Goodwill Goodwill	4404343000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3193032000	usd
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3328537000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	70157000	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	70661000	usd
CY2022Q2	us-gaap	Assets Assets	11188006000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	37553000	usd
CY2022Q1	us-gaap	Assets Assets	11423594000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	228987000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	225737000	usd
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	26873000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	137580000	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	183721000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35560000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36472000	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	151000000	usd
CY2022Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	142875000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	317643000	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	306544000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	908323000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	922222000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2846446000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	638693000	usd
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2945481000	usd
CY2022Q2	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	790819000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	780619000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150215000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	155056000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73075000	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	75579000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4768878000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	4878957000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	ste	Aggregate Amountof Shares Authorized AggregateAmountofSharesAuthorized	500000000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100090000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100067000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	4738746000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	4742920000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2057175000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1999244000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-388373000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-209808000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6407548000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	6532356000	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	11580000	usd
CY2022Q1	us-gaap	Minority Interest MinorityInterest	12281000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6419128000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6544637000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11188006000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11423594000	usd
CY2022Q2	us-gaap	Revenues Revenues	1156491000	usd
CY2021Q2	us-gaap	Revenues Revenues	968422000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	542140000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	517798000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	426282000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	334626000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	393752000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24751000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18192000	usd
CY2022Q2	us-gaap	Restructuring Costs RestructuringCosts	26000	usd
CY2021Q2	us-gaap	Restructuring Costs RestructuringCosts	14000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	359403000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	411958000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	158395000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	14324000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	22674000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	21812000	usd
CY2022Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	0	usd
CY2021Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	22923000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-770000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1434000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23444000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43301000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	134951000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28977000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24196000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7075000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	110755000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-507000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-95000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	111262000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-21807000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.11
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.10
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.43
CY2021Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.40
CY2022Q2	us-gaap	Profit Loss ProfitLoss	110755000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-507000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-95000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	111262000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-21807000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	-6000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	174000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	29000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-507000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-178594000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	24933000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-178565000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24426000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-67303000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2619000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	110755000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138863000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	83621000	usd
CY2022Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5304000	usd
CY2021Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	456000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	8963000	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	26600000	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	972000	usd
CY2021Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-824000	usd
CY2022Q2	ste	Loss On Sale Of Business LossOnSaleOfBusiness	-3878000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26335000	usd
CY2021Q2	ste	Loss On Sale Of Business LossOnSaleOfBusiness	-419000	usd
CY2022Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	0	usd
CY2021Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	22923000	usd
CY2022Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10412000	usd
CY2021Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2334000	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-41732000	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	58076000	usd
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1660000	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6755000	usd
CY2021Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6747000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6492000	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4614000	usd
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26963000	usd
CY2021Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-41892000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	231746000	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	97426000	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	115933000	usd
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56396000	usd
CY2022Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1288000	usd
CY2021Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	217000	usd
CY2022Q2	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	5228000	usd
CY2021Q2	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
CY2022Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	547353000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-109417000	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-603532000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	1350000000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	650000000	usd
CY2022Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	111875000	usd
CY2021Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	125000000	usd
CY2022Q2	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	usd
CY2021Q2	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-721284000	usd
CY2022Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	37011000	usd
CY2021Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-249421000	usd
CY2022Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2021Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	17227000	usd
CY2022Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	84000	usd
CY2021Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	25150000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	24679000	usd
CY2021Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10670000	usd
CY2022Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	43008000	usd
CY2021Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	34148000	usd
CY2022Q2	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1221000	usd
CY2021Q2	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1710000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-141414000	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	818810000	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-12908000	usd
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1539000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31993000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	314243000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	348320000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220531000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	316327000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	534774000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6544637000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	110755000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-178565000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	24679000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10182000	usd
CY2022Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.43
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	43008000	usd
CY2022Q2	ste	Increase Decrease In Noncontrolling Interests Other IncreaseDecreaseInNoncontrollingInterestsOther	194000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6419128000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3891468000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24426000	usd
CY2021Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10670000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28299000	usd
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.40
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	34148000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2689317000	usd
CY2021Q2	ste	Consideration Related To Equity Component Of Cantel Convertible Debt ConsiderationRelatedToEquityComponentOfCantelConvertibleDebt	175555000	usd
CY2021Q2	ste	Consideration Related To Cantel Equity Compensation Programs ConsiderationRelatedToCantelEquityCompensationPrograms	18173000	usd
CY2021Q2	ste	Reclassification To Cantel Convertible Debt Premium Liability ReclassificationToCantelConvertibleDebtPremiumLiability	175555000	usd
CY2021Q2	ste	Increase Decrease In Noncontrolling Interests Other IncreaseDecreaseInNoncontrollingInterestsOther	-52000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6585015000	usd
CY2022Q2	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations and Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal (“GI”) endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integrati</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and report in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. We describe our business segments in Note 9 titled, "Business Segment Information."</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. The Consolidated Balance Sheet at March 31, 2022 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2022 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Associated Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2022, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, $57,528 of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the March 31, 2022 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2022, $35,722 of the March 31, 2021 deferred revenue balance was recorded as revenue.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With reg</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2022, the transaction price allocated to remaining performance obligations was approximately $1,574,000. We expect to recognize approximately 62% of the transaction price within one year and approximately 31% beyond one year. The remainder has yet to be scheduled for delivery. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Impacting the Company</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards Impacting the Company are presented in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Adoption</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have been adopted in fiscal 2023</span></td></tr><tr style="height:5pt"><td colspan="27" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2022.</span></div>
CY2022Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2022 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2023.</span></div>
CY2022Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	57528000	usd
CY2021Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	35722000	usd
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1574000000	usd
CY2022Q2	ste	Cantel Acquisition Assumed Debt Obligations CantelAcquisitionAssumedDebtObligations	721284000	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Cash BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash	0	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Accounts Receivable BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable	0	usd
CY2022Q2	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Inventory BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory	0	usd
CY2022Q2	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Property Plant And Equipment BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment	-1282000	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Lease Right Of Use Assets Net BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLeaseRightOfUseAssetsNet	0	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Other Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets	0	usd
CY2022Q2	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Intangibles BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles	0	usd
CY2022Q2	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	22088000	usd
CY2022Q2	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Financial Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets	20806000	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Convertible Debt Par Value BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConvertibleDebtParValue	0	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Other Current Liabilities BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentLiabilities	5595000	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Long Term Lease Obligations BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLongTermLeaseObligations	0	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Deferred Income Taxes BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes	15211000	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Long Term Indebtedness BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLongTermIndebtedness	0	usd
CY2022Q2	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Financial Liabilities BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities	20806000	usd
CY2022Q2	ste	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Assets Acquired BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquired	0	usd
CY2022Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9832000	usd
CY2022Q2	us-gaap	Land Land	82795000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	211453000	usd
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	195035000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	107267000	usd
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	76021000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	341109000	usd
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	334880000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	39425000	usd
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	30937000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	620404000	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	574999000	usd
CY2022Q1	us-gaap	Land Land	84015000	usd
CY2022Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	651071000	usd
CY2022Q1	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	654851000	usd
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	899970000	usd
CY2022Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	903649000	usd
CY2022Q2	ste	Capitalized Computer Hardware Software Gross CapitalizedComputerHardwareSoftwareGross	223455000	usd
CY2022Q1	ste	Capitalized Computer Hardware Software Gross CapitalizedComputerHardwareSoftwareGross	222620000	usd
CY2022Q2	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	603761000	usd
CY2022Q1	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	597641000	usd
CY2022Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	402795000	usd
CY2022Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	356013000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2863847000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2818789000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1290510000	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1266213000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1573337000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1552576000	usd
CY2022Q2	ste	Term Loan Current Portion TermLoanCurrentPortion	27500000	usd
CY2022Q1	ste	Term Loan Current Portion TermLoanCurrentPortion	27500000	usd
CY2022Q2	ste	Delayed Draw Term Loan Current Portion DelayedDrawTermLoanCurrentPortion	32500000	usd
CY2022Q1	ste	Delayed Draw Term Loan Current Portion DelayedDrawTermLoanCurrentPortion	24375000	usd
CY2022Q2	us-gaap	Senior Notes Current SeniorNotesCurrent	91000000	usd
CY2022Q1	us-gaap	Senior Notes Current SeniorNotesCurrent	91000000	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	151000000	usd
CY2022Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	142875000	usd
CY2022Q2	us-gaap	Senior Notes SeniorNotes	745032000	usd
CY2022Q1	us-gaap	Senior Notes SeniorNotes	758726000	usd
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	92642000	usd
CY2022Q1	us-gaap	Line Of Credit LineOfCredit	58908000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	24353000	usd
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	25278000	usd
CY2022Q2	ste	Term Loan Non Current Portion TermLoanNonCurrentPortion	65625000	usd
CY2022Q1	ste	Term Loan Non Current Portion TermLoanNonCurrentPortion	177500000	usd
CY2022Q2	ste	Delayed Draw Term Loan Non Current Portion DelayedDrawTermLoanNonCurrentPortion	617500000	usd
CY2022Q1	ste	Delayed Draw Term Loan Non Current Portion DelayedDrawTermLoanNonCurrentPortion	625625000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	2846446000	usd
CY2022Q1	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	13669000	usd
CY2022Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	23174000	usd
CY2022Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	64702000	usd
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	2945481000	usd
CY2022Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	2997446000	usd
CY2022Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	3088356000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	83416000	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	71878000	usd
CY2022Q2	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	14108000	usd
CY2022Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	13598000	usd
CY2022Q1	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	30171000	usd
CY2022Q2	us-gaap	Other Postretirement Benefits Payable Current And Noncurrent OtherPostretirementBenefitsPayableCurrentAndNoncurrent	1190000	usd
CY2022Q1	us-gaap	Other Postretirement Benefits Payable Current And Noncurrent OtherPostretirementBenefitsPayableCurrentAndNoncurrent	1190000	usd
CY2022Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	2094000	usd
CY2022Q2	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	34450000	usd
CY2022Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	2111000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	137580000	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	183721000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	100617000	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	110791000	usd
CY2022Q2	ste	Serviceliabilities Serviceliabilities	47737000	usd
CY2022Q1	ste	Serviceliabilities Serviceliabilities	51365000	usd
CY2022Q2	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	11421000	usd
CY2022Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	8995000	usd
CY2022Q1	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	31700000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13443000	usd
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14108000	usd
CY2022Q2	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	517000	usd
CY2022Q1	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	1181000	usd
CY2022Q2	ste	Accrued Interest AccruedInterest	18073000	usd
CY2022Q1	us-gaap	Other Postretirement Benefits Payable Noncurrent OtherPostretirementBenefitsPayableNoncurrent	7335000	usd
CY2022Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	3601000	usd
CY2022Q1	ste	Accrued Interest AccruedInterest	10014000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	91385000	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	78390000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	317643000	usd
CY2022Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	306544000	usd
CY2022Q2	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	19213000	usd
CY2022Q1	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	19213000	usd
CY2022Q2	us-gaap	Other Postretirement Benefits Payable Noncurrent OtherPostretirementBenefitsPayableNoncurrent	7070000	usd
CY2022Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	1772000	usd
CY2022Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1183000	usd
CY2022Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1360000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	12502000	usd
CY2022Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	12225000	usd
CY2022Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	11897000	usd
CY2022Q2	ste	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0254
CY2022Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	12362000	usd
CY2022Q2	ste	Longtermliabilitiesother Longtermliabilitiesother	17609000	usd
CY2022Q1	ste	Longtermliabilitiesother Longtermliabilitiesother	21312000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73075000	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	75579000	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.179
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.244
CY2022Q2	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	12000000	usd
CY2022Q2	ste	Income Tax Examination Amount Of Loss Paid IncomeTaxExaminationAmountOfLossPaid	7500000	usd
CY2022Q2	ste	Uncertain Tax Liability Resulting From Irs Notice UncertainTaxLiabilityResultingFromIRSNotice	50000000	usd
CY2022Q2	ste	Amortizationandimpairmentofacquiredintangibleassets Amortizationandimpairmentofacquiredintangibleassets	93929000	usd
CY2021Q2	ste	Amortizationandimpairmentofacquiredintangibleassets Amortizationandimpairmentofacquiredintangibleassets	41741000	usd
CY2022Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9832000	usd
CY2021Q2	ste	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0285
CY2021Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	140996000	usd
CY2022Q2	ste	Tax Restructuring Costs TaxRestructuringCosts	173000	usd
CY2021Q2	ste	Tax Restructuring Costs TaxRestructuringCosts	-49000	usd
CY2022Q2	ste	Gain Loss On Fair Value Adjustment Of Acquisition Related Contingent Consideration GainLossOnFairValueAdjustmentOfAcquisitionRelatedContingentConsideration	-3100000	usd
CY2021Q2	ste	Gain Loss On Fair Value Adjustment Of Acquisition Related Contingent Consideration GainLossOnFairValueAdjustmentOfAcquisitionRelatedContingentConsideration	0	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-3878000	usd
CY2021Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-419000	usd
CY2022Q2	ste	Amortizationofinventoryandpropertystepuptofairvalue Amortizationofinventoryandpropertystepuptofairvalue	1637000	usd
CY2021Q2	ste	Amortizationofinventoryandpropertystepuptofairvalue Amortizationofinventoryandpropertystepuptofairvalue	24789000	usd
CY2022Q2	us-gaap	Restructuring Charges RestructuringCharges	26000	usd
CY2021Q2	us-gaap	Restructuring Charges RestructuringCharges	14000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	158395000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	14324000	usd
CY2022Q2	us-gaap	Revenues Revenues	1156491000	usd
CY2021Q2	us-gaap	Revenues Revenues	968422000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100082000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90152000	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	640000	shares
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	840000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100722000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90992000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0097
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.2445
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	ste	Deferred Ordinary Shares DeferredOrdinaryShares	25000	shares
CY2019Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	78979000	usd
CY2019Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	300000000	usd
CY2022Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	294649000	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	68177	shares
CY2022Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	14283000	usd
CY2022Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	57704	shares
CY2022Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11737000	usd
CY2021Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	59648	shares
CY2021Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10670000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2812252	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0241
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0116
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0080
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.2441
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	118.70
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1560954	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	138.37
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	222384	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	250.06
CY2022Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20640	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	53.20
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6326	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	200.62
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1756372	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	153.29
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	105081000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1109471	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	97397000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	624686	shares
CY2022Q2	ste	Common Stock Fair Market Value Per Share CommonStockFairMarketValuePerShare	206.15
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3897000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5469000	usd
CY2022Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1221000	usd
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1710000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	50.04
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	36.24
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	88105000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14108000	usd
CY2022Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3285000	usd
CY2022Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	3950000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13443000	usd
CY2022Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-936000	usd
CY2021Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-16000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10550000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7518000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-209808000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-178440000	usd
CY2022Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-125000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-178565000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-388373000	usd
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-61243000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	25524000	usd
CY2021Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-1098000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24426000	usd
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36817000	usd

Files In Submission

Name	View Source	Status
0001757898-22-000019-index-headers.html	Edgar Link	pending
0001757898-22-000019-index.html	Edgar Link	pending
0001757898-22-000019.txt	Edgar Link	pending
0001757898-22-000019-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ste-20220630.htm	Edgar Link	pending
ste-20220630.xsd	Edgar Link	pending
ste-20220630_def.xml	Edgar Link	unprocessable
ste06302022ex101.htm	Edgar Link	pending
ste06302022ex101001.jpg	Edgar Link	pending
ste06302022ex101002.jpg	Edgar Link	pending
ste06302022ex101003.jpg	Edgar Link	pending
ste06302022ex101004.jpg	Edgar Link	pending
ste06302022ex101005.jpg	Edgar Link	pending
ste06302022ex101006.jpg	Edgar Link	pending
ste06302022ex101007.jpg	Edgar Link	pending
ste06302022ex101008.jpg	Edgar Link	pending
ste06302022ex101009.jpg	Edgar Link	pending
ste06302022ex101010.jpg	Edgar Link	pending
ste06302022ex101011.jpg	Edgar Link	pending
ste06302022ex101012.jpg	Edgar Link	pending
ste06302022ex101013.jpg	Edgar Link	pending
ste06302022ex101014.jpg	Edgar Link	pending
ste06302022ex102.htm	Edgar Link	pending
ste06302022ex102001.jpg	Edgar Link	pending
ste06302022ex102002.jpg	Edgar Link	pending
ste06302022ex102003.jpg	Edgar Link	pending
ste06302022ex102004.jpg	Edgar Link	pending
ste06302022ex102005.jpg	Edgar Link	pending
ste06302022ex102006.jpg	Edgar Link	pending
ste06302022ex102007.jpg	Edgar Link	pending
ste06302022ex102008.jpg	Edgar Link	pending
ste06302022ex102009.jpg	Edgar Link	pending
ste06302022ex102010.jpg	Edgar Link	pending
ste06302022ex102011.jpg	Edgar Link	pending
ste06302022ex102012.jpg	Edgar Link	pending
ste06302022ex102013.jpg	Edgar Link	pending
ste06302022ex102014.jpg	Edgar Link	pending
ste06302022ex103.htm	Edgar Link	pending
ste06302022ex103001.jpg	Edgar Link	pending
ste06302022ex103002.jpg	Edgar Link	pending
ste06302022ex103003.jpg	Edgar Link	pending
ste06302022ex103004.jpg	Edgar Link	pending
ste06302022ex103005.jpg	Edgar Link	pending
ste06302022ex103006.jpg	Edgar Link	pending
ste06302022ex103007.jpg	Edgar Link	pending
ste06302022ex103008.jpg	Edgar Link	pending
ste06302022ex103009.jpg	Edgar Link	pending
ste06302022ex103010.jpg	Edgar Link	pending
ste06302022ex103011.jpg	Edgar Link	pending
ste06302022ex103012.jpg	Edgar Link	pending
ste06302022ex103013.jpg	Edgar Link	pending
ste06302022ex103014.jpg	Edgar Link	pending
ste06302022ex103015.jpg	Edgar Link	pending
ste-20220630_lab.xml	Edgar Link	unprocessable
ste-20220630_htm.xml	Edgar Link	completed
ste06302022ex151.htm	Edgar Link	pending
ste06302022ex311.htm	Edgar Link	pending
ste06302022ex312.htm	Edgar Link	pending
ste06302022ex321.htm	Edgar Link	pending
ste-20220630_cal.xml	Edgar Link	unprocessable
ste-20220630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STE
STERIS plc Stock $ste

2022 Q3 Form 10-Q Financial Statement

#000175789822000019 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STE STERIS plc Stock $ste

2022 Q3 Form 10-Q Financial Statement

#000175789822000019 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STE
STERIS plc Stock $ste